BCAX (Bicara Therapeutics) Other Financing: $1.58 Mil (TTM As of Mar. 2026)


BCAX Bicara Therapeutics Inc BCAX
12 GF Score
Price $28.35
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics Other Financing?

Bicara Therapeutics BCAX +5.51% 12 Other Financing is $1.58 Mil as of Mar. 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Bicara Therapeutics's Other Financing for the three months ended in Mar. 2026 was $1.58 Mil.

Bicara Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $1.58 Mil.

Bicara Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics Other Financing Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Financing
0.16 0.15 1.60 2.76

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.58
BCAX
12GF Score
Bicara Therapeutics Inc BCAX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $1.58 Mil mean?
Bicara Therapeutics (BCAX) has a Other Financing of $1.58 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Bicara Therapeutics and its competitors.
Is Bicara Therapeutics' Other Financing too high?
Bicara Therapeutics' current Other Financing is $1.58 Mil. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Other Financing compare to ZYME and SRPT?
Bicara Therapeutics' Other Financing of $1.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Bicara Therapeutics and its competitors. Bicara Therapeutics's current Other Financing is $1.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Other Financing of $1.58 Mil. The current Other Financing is $1.58 Mil. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Other Financing is $1.58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score

Get the complete analysis for BCAX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.35
Price